Investigation, treatment and monitoring of late-onsethypogonadism in males: The official guidelines of the International Society for the Study of the Aging Male (ISSAM), with comments;Diagnostic, traitement et surveillance de l'hypogonadisme de survenue tardive chez l'homme: Recommandations officielles de l'International Society for the Study of the Aging Male (ISSAM) et commentaires

Annales d'Endocrinologie

Volumn 64, Issue 4, 2003, Pages 289-304

  Cuzin, B ^a   Giuliano, F ^b   Jamin, Ch ^c   Legros, J J ^d   Lejeune, H ^a,f   Rigot, J M ^g   Roger, M ^e  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b BICÊTRE HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e HÔPITAL SAINT VINCENT DE PAUL   (France)

^f UNIVERSITÉ LYON 1   (France)

^g NONE

Author keywords

Aging; Andropause; Hypogonadism; Man; Replacement androgen therapy; Testosterone

Indexed keywords

ANDROGEN; FLUOXYMESTERONE; GROWTH HORMONE; LEPTIN; MELATONIN; METHYLTESTOSTERONE; PRASTERONE; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; THYROXINE;

AGING; ANDROGEN BLOOD LEVEL; ANDROGEN DEFICIENCY; ANDROGEN RELEASE; ANDROGEN REPLACEMENT THERAPY; ANDROPAUSE; FRANCE; HEART INFARCTION; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LIVER TOXICITY; MALE; MEDICAL SOCIETY; ONSET AGE; PATIENT MONITORING; PHYSICAL EXAMINATION; PROSTATE CANCER; PUBLICATION; RECTUM EXAMINATION; REVIEW;

AGING; ANDROGENS; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FRANCE; HORMONES; HUMAN GROWTH HORMONE; HUMANS; HYPOGONADISM; LANGUAGE; MALE; MELATONIN; PRACTICE GUIDELINES; QUESTIONNAIRES;

EID: 0142246508     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B. Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Horm Behav 1998; 33: 85-94.
2. Ammus SS. The role of androgens in the treatment of hematologic disorders. Adv Intern Med 1989; 34: 191-208.
3. Arlt W, Callies F, van Vlijmen JC et al. Dehydroepiandrosterone replacement in women with adrenal insuffiency. N Engl J Med 1999; 341: 1013-20.
4. Atkinson LE, Chang Y-L et al. Long-term experience with testosterone replacement through scrotal skin. In: Testosterone, Action, Deficiency, Substitution. Nieschlag E, Behre HM, eds. Springer Verlag, Berlin, 1998. pp. 365-38.
5. Baulieu EE, Thomas G, Legrain S et al. Dehydroepiandrosterone (DHEA), DHEA sulphate, and aging: contribution of DHEAge study to sociobiomedical issue. Proc Natl Acad Sci U S A 2000; 97: 4279-84.
6. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long term effect of testosterone therapy on bone density in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2386-90.
7. Conte-Devoix B. Le diagnostic des déficits en hormone de croissance (GH) chez l'adulte. Med Ther 2002; 4: 33-5.
8. Cooper D. Subclinical hypothyroidism. N Engl J Med 2001; 345: 260-5.
9. Costa P. Adénome prostatique, hormones et androgé nothérapie. Andrologie 2002; 12: 133-5.
10. Delhez M, Hansenne M, Legros JJ. Andropause and psychopathology: minor symptoms rather than pathological ones. Psychoneuroendocrinology 2003; 28: 863-74.
11. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc 1995; 43: 899-901.
12. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. A randomized, double-blind, placebo-controlled study. Circulation 2000; 102: 1906-11.
13. Flam T. Traitement androgénique substitutif et cancer prostatique. Andrologie 2002; 12: 136-7.
14. Gardner FH, Nathan DG, Piomelli S, Cummins JF. The erythrocytemic effects of androgens. Br J Haematol 1968; 14: 611-5.
15. Garry PJ, Goodwi JS, Hunt WC. Iron status and anemia in the elderly. J Am Geriatr Soc 1983; 31: 389-99.
16. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement therapy in older hypogonadal males: a retrospective study. J Clin Endocrinol Metab 1997; 82: 3793-6.
17. Heinemann LAJ, Zimmerman T, Vermeulen A, Thiel C, Hummel W. A new aging male symptoms rating scale. Aging Male 1999; 2: 105-114.
18. Hibberts NA, Howell AE, Randall VA. Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. J Endocrinol 1998; 156: 59-65.
19. Jamin C. HDL-cholesterol et steroïdes sexuels: la fin d'un mythe? Lettre Gynécol 2001; 258: 44-6.
20. Jockenhovel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 1997; 2: 293-8.
21. Kaufman JM. Androgens, bone metabolism and osteoporosis. In:. Androgens and the Aging male, Oddens B, Vermeulen A, eds. Parthenon Publishing, Carnforth, UK, 1996. pp 39-63.
22. Kennedy BJ, Gilbertson AS. Increased erythropoiesis induced by androgenic-hormone therapy. N Engl J Med 1957; 256: 719.
23. Kenny AM, Prestwood KM, Raisz LG. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol and hematocrit in men over age 70 with low testosterone levels. Endocr Res 2000; 26: 153-68.
24. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 56: M266-72.
25. st international consultation on erectile dysfunction, July 1-3, 1999, Paris. Jardin A, Wagner G, Khoury S, Giuliano F, Padma-Nathan H, Rosen R. eds. Health Publication Ltd, Plymbridge Distributors, Plymouth, 2000. pp. 207-240.
26. Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM. Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J Urol 1991; 146: 1566-70.
27. Legros JJ, Delhez M. Détection de la déficience androgénique chez l'homme de plus de 50 ans: utilisation d'une version française du test ADAM. Med Hyg 2002; 60: 1490-5.
28. Luboshitzky R, Aviv A, Hefetz A et al. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J Clin Endocrinol Metab 2002; 87: 3394-8.
29. Matsumoto AM, Sandblom RE, Schoene RB et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnea, respiratory drives, and sleep. Clin Endocrinol 1985; 22: 713-21.
30. Meikle AW. A permeation-enhanced non-scotal testosterone transdermal system for the treatment of male hypogonadism. In: Testosterone, Action, Deficiency, Substitution. Nieschlag E, Behre HM, eds. Springer Verlag, Berlin, 1998. pp. 390-422.
31. Morales A, Lunenfeld B. Androgen replacement therapy in aging male with secondary hypogonadism. Draft recommendations for endorment by ISSAM. Aging Male 2001; 4: 151-62.
32. Morales A, Lunenfeld B. Standards, guidelines and recommandations of the International Society for the Study of the Aging Male (ISSAM). Investigation, treatment and monitoring of lateonset hypogonadism in males. Official Recommandations of ISSAM. Aging Male 2002; 5: 74-86.
33. Morales A. Androgen replacement therapy and prostate safety. European Urology, 2002; 41: 113-20.
34. Morley JE, Charlton E, Patrick P et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239-42.
35. rd. Androgen deficiency in aging men: role of testosterone replacement therapy. J Lab Clin Med 2000; 135: 370-8.
36. Morris FK, Loy VE, et al. Hemoglobin concentration as determined by a methemoglobin method. Am J Clin Pathol 1956; 26: 1450-5.
37. Report of the National Institute on Aging Advisory Panel on testosterone replacement in men. J Clin Endocrinol Metab 2001; 86: 4611-4.
38. Roger M, Lahlou N. Le déficit androgénique lié à l'âge: du diagnostic biologique au traitement substitutif. Andrologie 2002; 12: 138-48.
39. Rosner W. Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab 1997; 82: 2014-5.
40. Schiavi RC, White D, Mandeli J. Pituitary-gonadal function during sleep in headline aging male. Psychoneuroendocrinology 1992; 17: 599-609.
41. Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1973; 289: 72-80.
42. rd, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12 month randomized controlled study. J Clin Endocrinol Metab 1997; 82: 1661-67.
43. Svetec DA, Canby ED, Thompson IM, Sabanegh ES Jr. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfonction. J Urol 1997; 158: 1775-7.
44. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092-8.
45. Tenover JS. Androgen administration to aging men. Endocrinol Metab Clin North Am 1994; 23: 877-92.
46. Tremblay RR, Morales A. Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging Male 1998; 1: 213-18.
47. Urban RJ, Bodenburg YH, Gilkinson C, Fowworth J, Coggan AR, Wolfe RR. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269 (5 Pt 1): E820-6.
48. Vermeulen A. Commentary to the article - low levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoproteins in normoglycemic men. J Clin Endocrinol Metab 1998; 83: 1822-3.
49. Vermeulen A, Verdonck L, Kaufman JL. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-72.
50. Winters SJ, Kelley DE, Goodpaster B. The analog free testosterone assay: are the results in men clinically useful? Clin Chem 1998; 44: 2178-82.
51. Zeitzer J, Daniels JE, Duffy JF et al. Do plasma melatonin concentrations decline with age? Am J Med 1999; 107: 432-6.